In this special edition podcast, Blood & Cancer revisits an interview with Gary H. Lyman, MD, of Fred Hutchinson Cancer Research Center, Seattle, on defining and understanding biosimilars. Dr. Lyman joins host David H. Henry, MD, to explore the interchangeability of these drugs and how biosimilars are being integrated into clinical practice guidelines.

*  *  *  

Help us make this podcast better! Please take our short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019

*  *  *  

This Week in Oncology

ASH preview: Key themes include tackling CAR T obstacles, sickle cell advances, VTE

By Sharon Worcester

Chimeric antigen receptor (CAR) T-cell therapies have garnered a great deal of attention given their “incredible efficacy” in treating B-cell malignancies, and new findings are taking aim at the drawbacks of therapy, such as the time, expense, and toxicity involved.

*  *  *  

For more MDedge Podcasts, go to mdedge.com/podcasts

Email the show: [email protected]

Interact with us on Twitter: @MDedgehemonc

David Henry on Twitter: @davidhenrymd

Ilana Yurkiewicz on Twitter: @ilanayurkiewicz